Published in J Am Chem Soc on June 28, 2008
Efficient drug lead discovery and optimization. Acc Chem Res (2009) 2.90
Alchemical free energy methods for drug discovery: progress and challenges. Curr Opin Struct Biol (2011) 2.31
Molecular dynamics simulations and drug discovery. BMC Biol (2011) 1.91
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem (2011) 1.68
Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization. J Am Chem Soc (2009) 1.52
Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations. J Comput Aided Mol Des (2010) 1.41
Entropy-enthalpy compensation: role and ramifications in biomolecular ligand recognition and design. Annu Rev Biophys (2013) 1.32
Prediction of the water content in protein binding sites. J Phys Chem B (2009) 1.27
Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J Am Chem Soc (2011) 1.10
Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. Bioorg Med Chem Lett (2010) 1.06
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem (2010) 1.06
The future of molecular dynamics simulations in drug discovery. J Comput Aided Mol Des (2011) 1.06
Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures. J Chem Inf Model (2009) 0.96
Enhanced Monte Carlo Sampling through Replica Exchange with Solute Tempering. J Chem Theory Comput (2014) 0.86
Structural characterization and computer-aided optimization of a small-molecule inhibitor of the Arp2/3 complex, a key regulator of the actin cytoskeleton. ChemMedChem (2012) 0.86
Vancomycin resistance: modeling backbone variants with D-Ala-D-Ala and D-Ala-D-Lac peptides. Bioorg Med Chem Lett (2008) 0.85
Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency. Bioorg Med Chem Lett (2012) 0.85
Computer-aided discovery of anti-HIV agents. Bioorg Med Chem (2016) 0.82
Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling. PLoS One (2012) 0.82
Accurate calculation of mutational effects on the thermodynamics of inhibitor binding to p38α MAP kinase: a combined computational and experimental study. J Chem Theory Comput (2013) 0.82
Molecular dynamics and Monte Carlo simulations for protein-ligand binding and inhibitor design. Biochim Biophys Acta (2014) 0.81
Path-integral method for predicting relative binding affinities of protein-ligand complexes. J Am Chem Soc (2009) 0.78
Identification of HIV inhibitors guided by free energy perturbation calculations. Curr Pharm Des (2012) 0.77
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World J Hepatol (2016) 0.77
Engineering tocopherol selectivity in α-TTP: a combined in vitro/in silico study. PLoS One (2012) 0.76
Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors. Mem Inst Oswaldo Cruz (2015) 0.75
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 14.70
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol (1991) 7.01
Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A (1991) 5.83
Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. Proc Natl Acad Sci U S A (2005) 4.15
Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. J Comput Chem (2005) 3.39
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A (2008) 2.82
Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.71
Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem (1988) 2.41
T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet (1984) 2.28
HIV drug development: the next 25 years. Nat Rev Drug Discov (2007) 2.00
The design of drugs for HIV and HCV. Nat Rev Drug Discov (2007) 1.85
Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. J Chem Theory Comput (2008) 1.80
Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol (1994) 1.66
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.58
Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. J Med Chem (2005) 1.48
Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett (2001) 1.44
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.38
FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc (2006) 1.36
Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. Antimicrob Agents Chemother (2002) 1.28
Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J Chem Inf Model (2007) 1.18
From docking false-positive to active anti-HIV agent. J Med Chem (2007) 1.16
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.15
Polarization Effects for Hydrogen-Bonded Complexes of Substituted Phenols with Water and Chloride Ion. J Chem Theory Comput (2007) 1.14
Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorg Med Chem Lett (2001) 1.02
Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. J Med Chem (2002) 0.89
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Type VI secretion: a beginner's guide. Curr Opin Microbiol (2008) 4.18
Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. Proc Natl Acad Sci U S A (2005) 4.15
An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natl Acad Sci U S A (2006) 3.89
Molecular modeling of organic and biomolecular systems using BOSS and MCPRO. J Comput Chem (2005) 3.39
xBASE2: a comprehensive resource for comparative bacterial genomics. Nucleic Acids Res (2007) 3.35
CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell (2011) 3.31
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med (2008) 3.28
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol Cell (2006) 2.21
Exchange of DNA base pairs that coincides with recognition of homology promoted by E. coli RecA protein. Mol Cell (2004) 1.95
Accuracy of free energies of hydration using CM1 and CM3 atomic charges. J Comput Chem (2004) 1.82
Bioinformatics analysis of the locus for enterocyte effacement provides novel insights into type-III secretion. BMC Microbiol (2005) 1.78
Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J Am Chem Soc (2015) 1.76
Bioinformatics, genomics and evolution of non-flagellar type-III secretion systems: a Darwinian perspective. FEMS Microbiol Rev (2005) 1.72
Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem (2005) 1.71
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem (2011) 1.68
Advances in quantum and molecular mechanical (QM/MM) simulations for organic and enzymatic reactions. Acc Chem Res (2010) 1.67
PDDG/PM3 and PDDG/MNDO: improved semiempirical methods. J Comput Chem (2002) 1.66
The ETT2 gene cluster, encoding a second type III secretion system from Escherichia coli, is present in the majority of strains but has undergone widespread mutational attrition. J Bacteriol (2004) 1.60
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.58
Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization. J Am Chem Soc (2009) 1.52
Macrophomate synthase: QM/MM simulations address the Diels-Alder versus Michael-Aldol reaction mechanism. J Am Chem Soc (2005) 1.47
Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J Med Chem (2006) 1.46
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2007) 1.43
Evolutionary links between FliH/YscL-like proteins from bacterial type III secretion systems and second-stalk components of the FoF1 and vacuolar ATPases. Protein Sci (2006) 1.43
Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res (2004) 1.42
Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem (2009) 1.39
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2006) 1.38
Relationship between side chain structure and 14-helix stability of beta3-peptides in water. J Am Chem Soc (2005) 1.36
FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Am Chem Soc (2006) 1.36
Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J Am Chem Soc (2012) 1.34
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry (2003) 1.32
The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal (2009) 1.29
A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc (2010) 1.29
Catalytic mechanism and performance of computationally designed enzymes for Kemp elimination. J Am Chem Soc (2008) 1.28
Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. Antimicrob Agents Chemother (2002) 1.28
Prediction of the water content in protein binding sites. J Phys Chem B (2009) 1.27
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
Large scale localization of protein phosphorylation by use of electron capture dissociation mass spectrometry. Mol Cell Proteomics (2009) 1.22
Extension of the PDDG/PM3 and PDDG/MNDO semiempirical molecular orbital methods to the halogens. J Comput Chem (2004) 1.21
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J Biol Chem (2004) 1.21
Steric retardation of SN2 reactions in the gas phase and solution. J Am Chem Soc (2004) 1.19
MRI of the wrist at 7 tesla using an eight-channel array coil combined with parallel imaging: preliminary results. J Magn Reson Imaging (2010) 1.18
Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring. J Chem Inf Model (2007) 1.18
Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J Am Chem Soc (2003) 1.17
Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer. J Am Chem Soc (2009) 1.17
Contributions of conformational compression and preferential transition state stabilization to the rate enhancement by chorismate mutase. J Am Chem Soc (2003) 1.17
Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci (2007) 1.16
From docking false-positive to active anti-HIV agent. J Med Chem (2007) 1.16
An antibody-recruiting small molecule that targets HIV gp120. J Am Chem Soc (2009) 1.15
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett (2005) 1.15
Exploring solvent effects upon the Menshutkin reaction using a polarizable force field. J Phys Chem B (2010) 1.15
Methyl effects on protein-ligand binding. J Med Chem (2012) 1.14
Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem (2002) 1.13
Improved Peptide and Protein Torsional Energetics with the OPLSAA Force Field. J Chem Theory Comput (2015) 1.13
Cope elimination: elucidation of solvent effects from QM/MM simulations. J Am Chem Soc (2006) 1.11
Conformation of alkanes in the gas phase and pure liquids. J Phys Chem B (2006) 1.11
Comparison of SCC-DFTB and NDDO-based semiempirical molecular orbital methods for organic molecules. J Phys Chem A (2006) 1.10
Selective peptide inhibitors of bifunctional thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights into domain-domain communication and allosteric regulation. Protein Sci (2013) 1.10
Why urea eliminates ammonia rather than hydrolyzes in aqueous solution. J Phys Chem B (2007) 1.10
Elucidation of fatty acid amide hydrolase inhibition by potent alpha-ketoheterocycle derivatives from Monte Carlo simulations. J Am Chem Soc (2005) 1.10
Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. J Am Chem Soc (2011) 1.10
Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. J Immunol Methods (2009) 1.10
Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues. J Med Chem (2004) 1.09